Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody: A Case Report

Immune checkpoint inhibitors (ICIs) are complicated by immune-related adverse events (irAEs), such as myositis, myocarditis, and myasthenia gravis (MG). Anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody are anti-striated antibodies that are frequently detected in MG patient...

Full description

Saved in:
Bibliographic Details
Published inInternal Medicine p. 8772-21
Main Authors Ono, Ryohei, Iwai, Yuta, Yamazaki, Tatsuro, Takahashi, Hidehisa, Hori, Yasuhiko, Fukushima, Kenichi, Saotome, Takashi
Format Journal Article
LanguageEnglish
Published Japan The Japanese Society of Internal Medicine 19.03.2022
Subjects
anti-striated antibody
anti-titin antibody
anti-voltage-gated potassium channel Kv1.4 antibody
immune checkpoint inhibitors
immune-related adverse events
nivolumab
anti-voltage-gated potassium channel Kv1.4 antibody
anti-titin antibody
immune checkpoint inhibitors
nivolumab
anti-striated antibody
immune-related adverse events
Online AccessGet full text

Cover

Abstract Immune checkpoint inhibitors (ICIs) are complicated by immune-related adverse events (irAEs), such as myositis, myocarditis, and myasthenia gravis (MG). Anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody are anti-striated antibodies that are frequently detected in MG patients with myositis and/or myocarditis. However, the clinical relationship between positive anti-striated antibodies and irAEs of ICIs remains unknown. We herein report a case of nivolumab-induced myositis and myocarditis with positive anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody in a patient with non-small-cell lung cancer. We also review reported cases of positive anti-striated antibodies related to irAEs of ICIs.
AbstractList Immune checkpoint inhibitors (ICIs) are complicated by immune-related adverse events (irAEs), such as myositis, myocarditis, and myasthenia gravis (MG). Anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody are anti-striated antibodies that are frequently detected in MG patients with myositis and/or myocarditis. However, the clinical relationship between positive anti-striated antibodies and irAEs of ICIs remains unknown. We herein report a case of nivolumab-induced myositis and myocarditis with positive anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody in a patient with non-small-cell lung cancer. We also review reported cases of positive anti-striated antibodies related to irAEs of ICIs.
Author Iwai, Yuta
Yamazaki, Tatsuro
Takahashi, Hidehisa
Saotome, Takashi
Ono, Ryohei
Hori, Yasuhiko
Fukushima, Kenichi
Author_xml – sequence: 1
  fullname: Ono, Ryohei
  organization: Department of Cardiology, Matsudo City General Hospital, Japan
– sequence: 2
  fullname: Iwai, Yuta
  organization: Department of Neurology, Matsudo City General Hospital, Japan
– sequence: 3
  fullname: Yamazaki, Tatsuro
  organization: Department of Cardiology, Matsudo City General Hospital, Japan
– sequence: 4
  fullname: Takahashi, Hidehisa
  organization: Department of Cardiology, Matsudo City General Hospital, Japan
– sequence: 5
  fullname: Hori, Yasuhiko
  organization: Department of Cardiology, Matsudo City General Hospital, Japan
– sequence: 6
  fullname: Fukushima, Kenichi
  organization: Department of Cardiology, Matsudo City General Hospital, Japan
– sequence: 7
  fullname: Saotome, Takashi
  organization: Department of Medical Oncology, Matsudo City General Hospital, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35314545$$D View this record in MEDLINE/PubMed
BookMark eNpdUdtOwzAMjRAIxuUXUH4go7n1wts0cRNXIeC1chOXZerSqcmG9h38MKXAHnixj-1zjmT7kOz61iMhlCdjwdPizPmInYdmgdYZ53GcZ5lggu-QEZeqYJmQepeMkoLnTPThgByGME8SmWeF2CcHUkuutNIj8vng1m2zWkDFnLcrg5beb9rgogsU_FAY6OxQf7g4o0_DcI104qNjscd-gFVrN4Ni6PeeEd6RvUPsHZ_aCCG41YJOZ-A9NvR2zcdqqzunEzqFgPQZl20Xj8leDU3Ak998RF4vL16m1-zu8epmOrljc54IzWxqtbVYqyyrjJJogGvDqyrHlHMlUm1Qg5F5XRXc2rrOeF0rJaFSKWiV1PKInP74LldVf8ly2bkFdJvy7zo94e2HMA_f22wJ0EVnGiz_v6EEu-69yuQPfL-lFHwrMDPoSvTyCy-vkYs
ContentType Journal Article
Copyright 2022 by The Japanese Society of Internal Medicine
Copyright_xml – notice: 2022 by The Japanese Society of Internal Medicine
DBID NPM
DOI 10.2169/internalmedicine.8772-21
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1349-7235
ExternalDocumentID 35314545
article_internalmedicine_advpub_0_advpub_8772_21_article_char_en
Genre Journal Article
GroupedDBID ---
.55
29J
2WC
3O-
53G
5GY
7.U
ACPRK
ADBBV
ADRAZ
AENEX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CS3
DIK
DU5
EBS
EJD
EMOBN
F5P
HYE
JSF
JSH
M48
M~E
OK1
P2P
RJT
RNS
RPM
RZJ
TKC
TR2
X7M
XSB
NPM
PGMZT
ID FETCH-LOGICAL-j1025-d6d5ddef477bc43eca15c1bb8e6114265ce5ac38fb91ddff71ff443ab46a540f3
IEDL.DBID M48
ISSN 0918-2918
IngestDate Sat Sep 28 08:21:55 EDT 2024
Sun Jul 28 05:37:13 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords anti-voltage-gated potassium channel Kv1.4 antibody
anti-titin antibody
immune checkpoint inhibitors
nivolumab
anti-striated antibody
immune-related adverse events
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-j1025-d6d5ddef477bc43eca15c1bb8e6114265ce5ac38fb91ddff71ff443ab46a540f3
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.2169/internalmedicine.8772-21
PMID 35314545
ParticipantIDs pubmed_primary_35314545
jstage_primary_article_internalmedicine_advpub_0_advpub_8772_21_article_char_en
PublicationCentury 2000
PublicationDate 2022-Mar-19
PublicationDateYYYYMMDD 2022-03-19
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-Mar-19
  day: 19
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle Internal Medicine
PublicationTitleAlternate Intern. Med.
PublicationYear 2022
Publisher The Japanese Society of Internal Medicine
Publisher_xml – name: The Japanese Society of Internal Medicine
References 4. Yamamoto AM, Gajdos P, Eymard B, et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 58: 885-890, 2001.
15. Schiopu SRI, Kasmann L, Schonermarck U, et al. Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy-case report. Transl Lung Cancer Res 10: 1039-1046, 2021.
13. Onda A, Miyagawa S, Takahashi N, et al. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy. Intern Med 58: 1635-1638, 2019.
5. Romi F, Suzuki S, Suzuki N, Petzold A, Plant GT, Gilhus NE. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol 259: 1312-1316, 2012.
12. Takahashi S, Mukohara S, Hatachi S, Yamashita M, Kumagai S. A case of myositis with dropped head syndrome and anti-titin antibody positivity induced by pembrolizumab. Scand J Rheumatol 49: 509-511, 2020.
11. Fazel M, Jedlowski PM. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Case Reports Immunol 2019: 2539493, 2019.
9. Thakolwiboon S, Karukote A, Wilms H. De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma. Cureus 11: e5002, 2019.
6. Suzuki S, Utsugisawa K, Nagane Y, et al. Classification of myasthenia gravis based on autoantibody status. Arch Neurol 64: 1121-1124, 2007.
17. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011: 740583, 2011.
20. Fazal M, Prentice DA, Kho LK, Fysh E. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies. Intern Med J 50: 1003-1006, 2020.
1. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29: 806-812, 2016.
7. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4: 36, 2016.
16. Gonzalez NL, Puwanant A, Lu A, Marks SM, Zivkovic SA. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. Neuromuscul Disord 27: 266-268, 2017.
19. Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91: e985-e994, 2018.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.
18. Cheng W, Sun T, Liu C, et al. A systematic review of myasthenia gravis complicated with myocarditis. Brain Behav 2021.
8. Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5: 91, 2017.
10. Sekiguchi K, Hashimoto R, Noda Y, et al. Diaphragm involvement in immune checkpoint inhibitor-related myositis. Muscle Nerve 60: E23-E25, 2019.
3. Rota E, Varese P, Agosti S, et al. Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life-threatening continuum of neuromuscular and cardiac toxicity. eNeurologicalSci 14: 4-5, 2019.
14. Jeyakumar N, Etchegaray M, Henry J, et al. The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma. Case Reports Immunol 2020: 5126717, 2020.
References_xml
SSID ssj0038792
Score 2.346373
Snippet Immune checkpoint inhibitors (ICIs) are complicated by immune-related adverse events (irAEs), such as myositis, myocarditis, and myasthenia gravis (MG)....
SourceID pubmed
jstage
SourceType Index Database
Publisher
StartPage 8772-21
SubjectTerms anti-striated antibody
anti-titin antibody
anti-voltage-gated potassium channel Kv1.4 antibody
immune checkpoint inhibitors
immune-related adverse events
nivolumab
Title Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody: A Case Report
URI https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8772-21/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/35314545
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Internal Medicine, 2022, pp.8772-21
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA6iIF7Et-uLHLx2bdo0TQWRRRQf7OrBBW8laRJYWbu6D3F_h3_YmbS7oIgnb0lLpiWTzHxJ5ssQcmxCZXSayUAkYAK5cVGgtMwC51yRWRlyxZHg3O6I6y6_fUqeFsiMrlh34OjXpR3mk-oO-82Pt-k5TPgzDGNmIjvpVXtn_dlpdFMCZAyQXb4UISEIA_r4_GwhlqlPlQyOEvkHTFbxPX9KAvf0DGANWfjfwKd3QldrZLVGj7RVqXudLNhygyy3azmb5LPT8-ZG6QDW2qA1Q9tTH5Y1oqr0lQKHBNZxB5Y--JfvlrbKcS_Ai4tKX9QDM_Ut_HOQib_l9-IMtBkD4u5NXihSE0rbp3ewBubzdqe0RS_AOdIK3G-R7tXl48V1UKddCJ4ZJrc1wiRg9BxPU13w2BaKJQXTWlqBxFuRFDZRRSydzpgxzqXMOc5jpblQgP9cvE0Wy0FpdwkVkeYMIJ8sTAYrR66MTZ1joQoNEzZiDXJf9Wv-Wt2tkdfzJf-piVyZd-j5PJwVUDN5xOYNkKQGM71BdioFzSXGYGU44MS9f__WPlmJkAyB0X3ZAVkcDyf2ECDKWB8BOL-5O_Lj7gsbQvKZ
link.rule.ids 315,783,787,24331,27937,27938
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nivolumab-induced+Myositis+and+Myocarditis+with+Positive+Anti-titin+Antibody+and+Anti-voltage-gated+Potassium+Channel+Kv1.4+Antibody%3A+A+Case+Report&rft.jtitle=Internal+Medicine&rft.au=Ono%2C+Ryohei&rft.au=Iwai%2C+Yuta&rft.au=Yamazaki%2C+Tatsuro&rft.au=Takahashi%2C+Hidehisa&rft.date=2022-03-19&rft.pub=The+Japanese+Society+of+Internal+Medicine&rft.issn=0918-2918&rft.eissn=1349-7235&rft.spage=8772-21&rft_id=info:doi/10.2169%2Finternalmedicine.8772-21&rft.externalDocID=article_internalmedicine_advpub_0_advpub_8772_21_article_char_en
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-2918&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-2918&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-2918&client=summon